Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 348 entries
View as:

A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05923424 Org: User:
Start: 11/28/23 End: 03/04/25 Due: 03/04/26

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Phase: N/A Priority: Normal
NCT ID: NCT02097524 Org: User:
Start: 03/31/14 End: 04/30/15 Due: 04/30/16

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Phase: N/A Priority: Normal
NCT ID: NCT04083534 Org: User:
Start: 09/26/19 End: 05/01/25 Due: 05/01/26

A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

Phase: N/A Priority: Normal
NCT ID: NCT06798298 Org: User:
Start: 05/30/25 End: 12/31/39 Due: 12/31/40

CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04633278 Org: User:
Start: 01/21/21 End: 01/19/24 Due: 01/19/25

Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT00320814 Org: User:
Start: 04/30/06 End: 08/31/07 Due: 08/31/08

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Phase: N/A Priority: Normal
NCT ID: NCT02447276 Org: User:
Start: 05/31/15 End: 11/30/16 Due: 11/30/17

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05338879 Org: User:
Start: 06/22/22 End: 10/05/23 Due: 10/05/24

Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Phase: N/A Priority: Normal
NCT ID: NCT02265952 Org: User:
Start: 02/04/15 End: 07/23/18 Due: 07/23/19

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Phase: N/A Priority: Normal
NCT ID: NCT03710941 Org: User:
Start: 02/19/19 End: 11/05/20 Due: 11/05/21

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Phase: N/A Priority: Normal
NCT ID: NCT01161082 Org: User:
Start: 06/30/10 End: 05/31/11 Due: 05/31/12

Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Phase: N/A Priority: Normal
NCT ID: NCT01639040 Org: User:
Start: 07/31/12 End: 12/31/12 Due: 12/31/13

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04888507 Org: User:
Start: 07/08/21 End: 05/04/23 Due: 05/04/24

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT01949311 Org: User:
Start: 10/10/13 End: 06/27/22 Due: 06/27/23

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Phase: N/A Priority: Normal
NCT ID: NCT05989126 Org: User:
Start: 04/15/24 End: 05/31/24 Due: 05/31/25

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Phase: N/A Priority: Normal
NCT ID: NCT04863014 Org: User:
Start: 07/12/21 End: 02/15/23 Due: 02/15/24

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05203380 Org: User:
Start: 01/27/22 End: 03/10/23 Due: 03/10/24

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Phase: N/A Priority: Normal
NCT ID: NCT02325791 Org: User:
Start: 07/21/15 End: 09/26/17 Due: 09/26/18

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

Phase: N/A Priority: Normal
NCT ID: NCT05744921 Org: User:
Start: 03/07/23 End: 02/26/29 Due: 02/26/30

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04811716 Org: User:
Start: 07/29/21 End: 10/18/23 Due: 10/18/24

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06091254 Org: User:
Start: 12/12/23 End: 04/04/29 Due: 04/04/30

Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study

Phase: N/A Priority: Normal
NCT ID: NCT03379558 Org: User:
Start: 12/19/17 End: 09/04/20 Due: 09/04/21

Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03746704 Org: User:
Start: 09/04/19 End: 07/08/21 Due: 07/08/22

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06149286 Org: User:
Start: 12/28/23 End: 01/23/29 Due: 01/23/30

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Phase: N/A Priority: Normal
NCT ID: NCT03198130 Org: User:
Start: 07/03/17 End: 02/21/20 Due: 02/21/21